| |
| Hepatitis B - Newer Trends in Epidemiology and Treatment |
| Clifford Hale, MD, FACP, MBA, DBIM |
|
|
| |
|
This presentation will enable underwriters to use hepatitis B serology to
differentiate among those who are vaccinated, cured, carriers, partially
treated, or treatment failures. Risk implications of hepatic fibrosis including
cirrhosis and hepatic cell carcinoma will be explained along with the current
means for assessing the presence or likelihood of fibrosis.
|
| |
|
